CHMP backs GSK’s lupus drug for kidney complication, J&J’s oral MS therapy

GSK’s Benlysta and J&J’s Ponvory are two of the latest therapies to win support from EMA’s CHMP, which did not issue any negative recommendations in March.

The agency recommended a label extension for Benlysta belimumab to treat active lupus nephritis, a complication of systemic lupus erythematosus (SLE), in combination with background immunosuppression. The mAb against BlyS from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) is already indicated in the EU for active, autoantibody-positive SLE with a high degree of disease activity...